Ascendis Pharma’s total revenue decreases 50% to €1.9 million in second quarter 2015
Ascendis Pharma A/S, a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced financial results for the three and six months ended June 30, 2015.